Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KOfactor1 is a proprietary nutraceutical formulation developed by NewG Lab Pharma in collaboration with KoDiscovery. It consists of a synergistic combination of three active ingredients: luteolin (a flavonoid), rutin (a flavonoid), and epigallocatechin-3-gallate (EGCG, a polyphenol from green tea). The product is designed to target the Warburg Effect, a metabolic hallmark of cancer cells characterized by a reliance on aerobic glycolysis. By synergistically affecting multiple cellular mechanisms, KOfactor1 aims to reduce the availability of energy substrates to cancer cells and induce apoptosis without negatively impacting healthy cells. The formulation is based on internal data demonstrating enhanced efficacy in killing cancer cells when these three compounds are combined in a specific ratio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KOfactor1.